Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mirum Pharmaceuticals (MIRM) Receivables (2021 - 2025)

Mirum Pharmaceuticals (MIRM) has 5 years of Receivables data on record, last reported at $123.3 million in Q4 2025.

  • For Q4 2025, Receivables rose 57.54% year-over-year to $123.3 million; the TTM value through Dec 2025 reached $123.3 million, up 57.54%, while the annual FY2025 figure was $123.3 million, 57.54% up from the prior year.
  • Receivables reached $123.3 million in Q4 2025 per MIRM's latest filing, up from $107.1 million in the prior quarter.
  • Across five years, Receivables topped out at $123.3 million in Q4 2025 and bottomed at $400000.0 in Q3 2021.
  • Average Receivables over 5 years is $52.1 million, with a median of $51.4 million recorded in 2023.
  • Peak YoY movement for Receivables: soared 3984.25% in 2022, then grew 15.18% in 2024.
  • A 5-year view of Receivables shows it stood at $3.3 million in 2021, then surged by 634.44% to $24.0 million in 2022, then skyrocketed by 183.27% to $68.0 million in 2023, then grew by 15.18% to $78.3 million in 2024, then surged by 57.54% to $123.3 million in 2025.
  • Per Business Quant database, its latest 3 readings for Receivables were $123.3 million in Q4 2025, $107.1 million in Q3 2025, and $106.8 million in Q2 2025.